SUPPLEMENTARY APPENDIX

Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis

Seock-Ah Im, Binghe Xu, Wei Li, Mark Robson, Quchang Ouyang, Dah-Cherng Yeh, Hiroji Iwata, Yeon Hee Park, Joo Hyuk Sohn, Ling-Ming Tseng, Carsten Goessl, Wenting Wu, Norikazu Masuda
Supplementary Fig. 1 Patient flow diagram

87 patients randomised

59 olaparib (FAS)

28 chemotherapy (FAS)

1 patient withdraw (patient decision)

59 received treatment

49 patients discontinued study treatment:
- 41 disease progression
- 4 adverse events
- 4 patient decision

27 patients discontinued study treatment:
- 23 disease progression
- 2 adverse events
- 2 patient decision

10 patients ongoing treatment at data cut-off

0 patients ongoing treatment at data cut-off